EUVIMEDEUVIMED entdecken
Crossref

ระดบภมคมกนตอเชอ SARS-CoV-2 ภายหลงการฉดวคซน ChAdOx1 nCoV-19 ในผปวยเบาหวานชนดท 2 ทรบการรกษาในวชรพยาบาล: Antibody Response after Covid-19 Vaccination in T2DM

Orawan Jedsadatud, Swangjit Suraamornkul

Vajira Medical Journal: Journal of Urban Medicine · 16.03.2023

DOI: 10.14456/vmj.2023.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vajira Medical Journal: Journal of Urban Medicine, erschienen am 16.03.2023. Verfasst von Orawan Jedsadatud und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: A question exists as to whether people with diabetes can respond effectively to the COVID-19 vaccine. This study aimed to evaluate antibody response after COVID-19 vaccination in patients with type 2 diabetes.METHODS: This was a cross-sectional analytical study. Two hundred and twelve type 2 diabetes patients were enrolled after receiving a second dose of the ChAdOx1nCoV-19vaccine 3 months previously. Demographic data, medical history, and blood drawn were collected. Antibodies against receptor binding domain (anti-RBD) was investigated in the laboratory department. Other factors that could affect anti-RBD level, i.e. age, gender, BMI, glycemic control, duration of diabetes, and comorbidity, were collected and analyzed.RESULTS: Among 212 patients with type 2 diabetes 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine, the anti-RBD level mean was 989.56 U/ml. Patients with type 2 diabetes, with or without cardiovascular disease as a comorbidity, had median anti-RBD levels equal to 258 U/ml and 442 U/ml, respectively. The median of anti-RBD levels between groups had statistically significant differences (p-value = 0.021). Age, gender, BMI, duration of diabetes, glycemic control, and other comorbidities showed no statistically significant differences in the median anti-RBD levels.CONCLUSION: Only patients with type 2 diabetes with cardiovascular disease as a comorbidity showed statistically significant differences in Anti-SARS-CoV-2 response 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine. Therefore, patients with diabetes and cardiovascular disease require earlier revaccination to ensure protection against COVID-19 infection.

Schlagwörter

COVID-19 vaccinationSARS-CoV-2type 2 diabetesChAdOx1 nCoV-19 vaccineanti-RBD antibodieshumoral immune responsecardiovascular comorbidityglycemic control

Zitieren

APA

Jedsadatud, O., & Suraamornkul, S. (2023). ระดบภมคมกนตอเชอ SARS-CoV-2 ภายหลงการฉดวคซน ChAdOx1 nCoV-19 ในผปวยเบาหวานชนดท 2 ทรบการรกษาในวชรพยาบาล: Antibody Response after Covid-19 Vaccination in T2DM. Vajira Medical Journal: Journal of Urban Medicine. https://doi.org/10.14456/vmj.2023.4

Vancouver

Jedsadatud O, Suraamornkul S. ระดบภมคมกนตอเชอ SARS-CoV-2 ภายหลงการฉดวคซน ChAdOx1 nCoV-19 ในผปวยเบาหวานชนดท 2 ทรบการรกษาในวชรพยาบาล: Antibody Response after Covid-19 Vaccination in T2DM. Vajira Medical Journal: Journal of Urban Medicine. 2023. doi:10.14456/vmj.2023.4

BibTeX
@article{Jedsadatud2023,
  author = {Jedsadatud, Orawan and Suraamornkul, Swangjit},
  title = {ระดบภมคมกนตอเชอ SARS-CoV-2 ภายหลงการฉดวคซน ChAdOx1 nCoV-19 ในผปวยเบาหวานชนดท 2 ทรบการรกษาในวชรพยาบาล: Antibody Response after Covid-19 Vaccination in T2DM},
  journal = {Vajira Medical Journal: Journal of Urban Medicine},
  year = {2023},
  doi = {10.14456/vmj.2023.4}
}
Kostenlos starten →